Aortic Aneurysm Market Size, Share, Growth, and Industry Analysis, By Type (Medicine, Surgery, Other), By Application (Hospital, Clinic, Other), Regional Insights and Forecast From 2026 To 2035

Aortic Aneurysm Market Overview

The global aortic aneurysm market size is estimated at USD 2927.26 Million in 2026, set to expand to USD 4464 Million by 2035, growing at a CAGR of 4.8% during the forecast from 2026 to 2035.

The global aortic aneurysm market includes medicines, surgical procedures, endovascular grafts, diagnostic imaging, monitoring systems, and supporting hospital services used for aneurysm management. Abdominal aortic aneurysm remains a major treatment segment, while thoracic aneurysm care increasingly uses minimally invasive endovascular techniques. Endovascular aneurysm repair provides an alternative to open surgery by placing a stent graft through vascular access rather than directly opening the aorta. Medtronic reports that its Endurant family has treated more than 450,000 patients worldwide, demonstrating the scale of established endovascular adoption. The market is also shaped by ageing populations, hypertension, smoking, imaging availability, specialist vascular centers, and continued development of fenestrated, branched, conformable, and thoracic stent-graft technologies.

The United States remains a major market for aortic aneurysm diagnosis and treatment because of advanced vascular-care infrastructure, broad availability of computed tomography angiography, specialist surgeons, and established reimbursement pathways. The country has substantial adoption of endovascular aneurysm repair, including emergency treatment for ruptured abdominal aortic aneurysms. In October 2025, Medtronic received United States regulatory labeling approval removing a warning concerning emergency treatment of ruptured abdominal aortic aneurysms for its Endurant stent graft system. United States demand is further supported by ageing demographics, cardiovascular disease management, vascular screening initiatives, and investment in devices that improve deployment accuracy, proximal sealing, fixation, and long-term surveillance.

Key Findings

• By Type, Surgery leads with 44% share, while Medicine is fastest-growing at 5.1% CAGR, supported by cardiovascular risk management measures.
• By Application, Hospital leads with 61% share and records 4.9% CAGR, driven by complex procedures, emergency care, and specialist infrastructure.
• By Geography, North America leads with 38.3% share, while Asia Pacific grows fastest at 6.1% CAGR, supported by healthcare modernization.

Aortic Aneurysm Market Latest Trends

The aortic aneurysm market is shifting toward minimally invasive treatment, personalized device selection, emergency endovascular repair, and technologies designed for challenging anatomy. Endovascular aneurysm repair remains central to abdominal aneurysm management because stent grafts can exclude the aneurysm sac from blood flow while avoiding direct surgical opening of the aorta. Current product development increasingly emphasizes proximal sealing, fixation, conformability, delivery control, and compatibility with complex aortic anatomy. Medtronic's clinical evidence programs include approximately 550 patients across 60 global sites in the ADVANCE program, while other studies address wide-neck and short-neck abdominal aneurysms.

Another important trend is expanding attention to ruptured aneurysm treatment. In 2025 and 2026, regulatory updates for Medtronic and Gore devices addressed labeling associated with ruptured abdominal aneurysm treatment. Manufacturers are also refining manufacturing processes, delivery components, reinforcement materials, sterilization arrangements, and graft configurations to improve product consistency and clinical usability. Gore received a 2026 regulatory approval for modification of the second deployment fiber used in several Excluder devices, illustrating continued attention to controlled delivery technology.

Aortic Aneurysm Market Dynamics

DRIVER

"Rising adoption of minimally invasive endovascular aneurysm repair."

The strongest driver for the aortic aneurysm market is increasing preference for minimally invasive treatment when patient anatomy permits endovascular intervention. Endovascular aneurysm repair uses a stent graft delivered through vascular access, reducing the need for direct surgical opening of the aorta. This approach supports demand for abdominal and thoracic endovascular grafts, delivery systems, fixation technologies, and imaging equipment. An ageing population also increases the number of patients requiring aneurysm assessment and surveillance. Hypertension, smoking history, atherosclerotic disease, and family history remain important risk factors that increase clinical attention. Hospitals are additionally investing in vascular imaging and hybrid operating capabilities, allowing specialists to manage increasingly complex aneurysm anatomies. The availability of fenestrated, branched, conformable, and endosuture technologies is expanding treatment options beyond standard infrarenal aneurysms. Medtronic's HERCULES trial, for example, is designed to compare endosuture aneurysm repair with standard EVAR in patients with wide proximal necks, demonstrating the industry's focus on expanding minimally invasive treatment to anatomically challenging patients.

RESTRAINT

"Anatomical limitations and long-term surveillance requirements."

A major restraint is that not every aneurysm patient is anatomically suitable for standard endovascular repair. Aortic neck length, neck diameter, angulation, iliac anatomy, vascular access, calcification, and thrombus can influence device selection and procedural feasibility. Complex anatomy may require fenestrated, branched, chimney, or adjunctive technologies, increasing procedural planning and technical requirements. Long-term surveillance is another important consideration. Current clinical guidance recommends computed tomography surveillance after EVAR at 1 month, followed by duplex ultrasound at 12 months and annually when appropriate, with additional cross-sectional imaging every 5 years considered reasonable in selected patients. Endoleaks, graft migration, limb occlusion, aneurysm enlargement, renal complications, and vascular-access complications can also require secondary procedures. These clinical requirements can increase hospital workload, imaging utilization, specialist dependence, and overall treatment complexity.

OPPORTUNITY

"Expansion of advanced endovascular technologies for complex aneurysm anatomy."

Significant opportunities exist in devices capable of treating aneurysms that cannot be managed effectively with conventional graft configurations. Fenestrated and branched endovascular grafts can support treatment near important visceral or branch vessels, while endosuture technologies can reinforce proximal fixation and sealing. Medtronic's Heli-FX EndoAnchor system is designed to provide additional fixation and sealing between an endovascular graft and the native artery, supporting treatment of migration or endoleak risks. Another opportunity involves emergency treatment of ruptured abdominal aneurysms. Regulatory developments in 2025 and 2026 show manufacturers working to expand clinical evidence and labeling for emergency applications. Emerging markets also offer opportunities because vascular disease awareness, diagnostic imaging availability, specialist training, and access to minimally invasive procedures continue to improve. Product companies can strengthen growth opportunities through physician education, local distribution, clinical partnerships, and manufacturing capacity.

CHALLENGE

"Managing device durability, procedural complications, and increasingly complex patient anatomy."

Long-term clinical performance remains a major challenge because aneurysm treatment does not end when the graft is implanted. Patients may require years of imaging surveillance to detect endoleaks, migration, sac enlargement, limb problems, or other device-related events. Manufacturers therefore face pressure to demonstrate durability while maintaining small delivery profiles and precise deployment. Complex aneurysm anatomy creates additional technical challenges because standard devices may not provide adequate sealing or fixation. Regulatory requirements also demand extensive evidence concerning safety, effectiveness, manufacturing consistency, labeling, and post-market performance. Product recalls, adverse-event reports, and corrective modifications can affect physician confidence and hospital procurement decisions. The market must also balance innovation with affordability because advanced fenestrated, branched, and custom-configured devices require specialized planning and clinical expertise. These challenges encourage manufacturers to improve materials, delivery systems, imaging compatibility, deployment control, and long-term clinical evidence.

Aortic Aneurysm Market Segmentation

By Type

• Medicine: Medicine represents an estimated 31% share of the categorized aortic aneurysm treatment market. Pharmaceutical treatment does not generally remove an established aneurysm but plays an important role in managing cardiovascular risk factors and slowing disease progression. Blood-pressure control, lipid management, smoking cessation support, and antiplatelet or other cardiovascular therapies can form part of comprehensive patient management depending on clinical circumstances. The medicine segment benefits from the growing emphasis on preventive cardiovascular care and risk-factor management. Patients undergoing surveillance may receive medical management while clinicians monitor aneurysm dimensions through imaging. The increasing availability of primary-care cardiovascular assessment can support earlier identification of high-risk individuals. Medicine also complements surgical and endovascular treatment because patients frequently require cardiovascular risk management before and after intervention. The segment therefore remains important despite the procedural nature of definitive aneurysm repair.
• Surgery: Surgery accounts for an estimated 44% share of the categorized aortic aneurysm treatment market, making it the largest treatment category in this segmentation. Open surgical repair remains an important option for patients with anatomy unsuitable for endovascular devices, complex aneurysm configurations, selected younger patients, and certain emergency situations. Surgical repair involves replacing the diseased aortic segment with a synthetic graft and requires direct operative access. The segment benefits from established clinical experience, durable graft technologies, specialist vascular-surgery expertise, and hospital infrastructure. However, the availability of minimally invasive alternatives creates competitive pressure on conventional open procedures. Advanced surgical centers continue to maintain capability because complicated thoracic, abdominal, and ruptured aneurysms may require open or hybrid approaches. Continued improvements in perioperative care, anesthesia, blood management, and graft technology support the role of surgery in the global aortic aneurysm market.
• Other: Other treatment approaches represent an estimated 25% share of the categorized treatment market and include endovascular procedures, hybrid procedures, surveillance-based management, adjunctive interventions, and specialized device-assisted treatment. This segment is increasingly important because aortic aneurysm management is becoming more individualized according to anatomy and clinical risk. Endovascular repair can exclude the aneurysm sac from blood flow without directly opening the aorta, while hybrid procedures combine surgical and endovascular techniques. Endosuture systems, iliac branch technologies, fenestrated grafts, and thoracic stent grafts broaden treatment options. The category is also supported by improvements in computed tomography planning, three-dimensional reconstruction, image-guided intervention, and postoperative surveillance. Continued product development is expected to strengthen demand for specialized technologies capable of addressing short necks, wide necks, branch vessels, tortuous access routes, and thoracic pathology.

By Application

• Hospital: Hospitals represent an estimated 61% share of the categorized application market. Hospitals remain the dominant setting because aneurysm diagnosis, emergency management, surgery, EVAR, TEVAR, intensive monitoring, and postoperative imaging require multidisciplinary infrastructure. Major hospitals can maintain vascular surgery teams, interventional specialists, anesthesiology support, advanced computed tomography, hybrid operating rooms, blood-management services, and emergency departments. The hospital segment also benefits from access to large inventories of endovascular devices and specialist equipment. Complex aneurysms frequently require multidisciplinary planning involving vascular surgeons, cardiologists, radiologists, and interventional teams. Emergency ruptured aneurysms further strengthen hospital demand because patients require rapid imaging and immediate intervention. The availability of endovascular and open procedures under one institutional structure allows hospitals to select treatment according to anatomy and clinical urgency.
• Clinic: Clinics account for an estimated 24% share of the categorized application market. Clinics play a significant role in screening, follow-up consultations, cardiovascular risk management, postoperative monitoring, and referral of suspected aneurysm cases to specialist hospitals. Advances in vascular ultrasound support outpatient surveillance for selected patients, reducing dependence on repeated hospital visits when clinically appropriate. Clinics also provide opportunities for earlier detection among patients with hypertension, smoking history, cardiovascular disease, or family history. The clinic segment is closely connected to the hospital segment because patients identified with significant aneurysms generally require specialist imaging and treatment planning. Growth in outpatient vascular services, diagnostic centers, and specialist consultations can strengthen this application category. Clinics also support long-term patient education, medication adherence, lifestyle modification, and surveillance compliance after endovascular procedures.
• Other: Other applications represent an estimated 15% share and include ambulatory diagnostic centers, specialty imaging facilities, rehabilitation services, research institutions, and healthcare environments involved in long-term aneurysm monitoring. These settings can support computed tomography, ultrasound, vascular assessment, patient education, and research activities without requiring every interaction to occur inside a hospital. The category is becoming more relevant as healthcare systems seek to shift suitable follow-up services toward lower-cost outpatient environments. Remote monitoring and digital imaging transfer may also support specialist review across geographic locations. Research institutions contribute through clinical trials evaluating graft durability, endovascular techniques, and complex-anatomy interventions. The other application segment therefore provides supporting infrastructure around hospital-based treatment and clinic-based follow-up, helping create a more integrated pathway from diagnosis through long-term surveillance.

Aortic Aneurysm Market Regional Outlook

• North America

North America accounts for an estimated 30% of the geographic market structure and remains one of the strongest regions for aortic aneurysm diagnosis and treatment. The United States dominates regional demand because of advanced vascular centers, high imaging utilization, specialist surgeons, and established endovascular device availability. Endovascular aneurysm repair is widely integrated into vascular practice, while thoracic endovascular aneurysm repair provides minimally invasive treatment for suitable descending thoracic aortic disease. Medtronic reports more than 450,000 global patients treated with its Endurant II/IIs platform, reflecting the maturity of the regional endovascular ecosystem. The United States also recorded regulatory activity in 2025 concerning emergency ruptured abdominal aneurysm treatment, while Gore received a similar labeling update for its Excluder Conformable platform in 2026. Canada contributes through specialist cardiovascular centers and growing endovascular capabilities. Regional opportunities include complex aneurysm devices, emergency treatment, physician training, advanced imaging, and long-term surveillance technologies.

• Europe

Europe represents an estimated 24% share of the geographic market structure. The region has mature vascular surgery systems, specialist cardiovascular hospitals, established endovascular programs, and extensive clinical experience with abdominal and thoracic aneurysm treatment. Germany, the United Kingdom, France, Italy, Spain, and Nordic countries contribute significantly to European demand. European treatment patterns increasingly emphasize minimally invasive repair where anatomy permits, while open surgery remains essential for selected complex cases. Terumo reports that the transition from surgical treatment toward vascular intervention is an important market trend and identifies growth opportunities in emerging markets associated with advances in medical technologies. European demand is also supported by ageing populations and established screening and surveillance pathways. Clinical research remains important, with multinational studies evaluating durability, sac regression, fixation, and treatment of complex neck anatomies. Regulatory requirements, reimbursement differences, and country-specific procurement systems remain important factors influencing product adoption.

• Germany Aortic Aneurysm Market Insights

Germany represents an estimated 7% share of the geographic structure used in this report. The country has advanced vascular surgery infrastructure, comprehensive hospital services, high diagnostic imaging capacity, and strong medical-device expertise. German hospitals provide open repair, EVAR, TEVAR, and complex endovascular procedures for appropriately selected patients. The ageing population supports continued demand for aneurysm diagnosis and surveillance, while cardiovascular risk management remains an important component of patient care. German centers also participate in European clinical research and physician training programs involving advanced endovascular technologies. Regulatory and procurement requirements encourage manufacturers to demonstrate device quality, clinical performance, and long-term reliability. The market benefits from specialist vascular teams and access to hybrid operating facilities. Medtronic's Valiant thoracic system has regulatory documentation involving a sterilization site in Germany, demonstrating the country's relevance within the medical-device supply ecosystem.

• United Kingdom Aortic Aneurysm Market Insights

The United Kingdom accounts for an estimated 5% share of the geographic structure. The country has an established national abdominal aortic aneurysm screening framework and specialist vascular services that support diagnosis and treatment. Hospital vascular teams provide open repair and endovascular repair according to anatomy, patient characteristics, and clinical circumstances. The United Kingdom also contributes to clinical research concerning aneurysm surveillance, repair strategies, postoperative outcomes, and healthcare resource utilization. Demand is supported by an ageing population and the continued need to identify patients before rupture. Endovascular procedures are increasingly important where suitable anatomy permits minimally invasive treatment. Specialist hospitals also maintain emergency capabilities for ruptured aneurysms. The United Kingdom market presents opportunities for advanced grafts, imaging technologies, postoperative monitoring, and devices designed for challenging anatomy. Procurement decisions remain sensitive to clinical outcomes, procedural efficiency, durability, and healthcare-system cost considerations.

• Asia

Asia represents an estimated 22% share of the geographic market structure and offers substantial long-term opportunities because of its large population, ageing demographics, increasing cardiovascular disease burden, and expanding specialist infrastructure. Japan and China are major contributors, while South Korea, India, Australia, Singapore, and other markets are developing advanced vascular intervention capacity. Endovascular adoption is increasing as hospitals invest in hybrid operating rooms, computed tomography angiography, catheterization facilities, and specialist training. Japan has a mature medical-device environment, while China is expanding cardiovascular hospitals and domestic medical-device capabilities. Across Asia, awareness of aneurysm diagnosis and cardiovascular risk management is improving. Device manufacturers are increasingly targeting smaller delivery profiles, conformable grafts, and complex anatomy. The region also offers opportunities for physician education and localized manufacturing. Terumo identifies emerging-market growth associated with technological advancement and lifestyle changes that increase Western-type cardiovascular diseases, supporting the broader strategic importance of Asian markets.

• Japan Aortic Aneurysm Market Insights

Japan represents an estimated 5% share of the geographic structure. The country has an ageing population, sophisticated cardiovascular hospitals, advanced imaging infrastructure, and experienced vascular specialists. Japanese hospitals use open and endovascular techniques according to aneurysm anatomy and patient characteristics. The ageing demographic supports demand for aneurysm surveillance and minimally invasive procedures because clinicians increasingly seek treatments compatible with older and medically complex patients. Japan is also an important clinical market for global device manufacturers because regulatory approvals, physician experience, and clinical evidence influence adoption. Product opportunities include thoracic and abdominal stent grafts, branched technologies, advanced delivery systems, and imaging-assisted planning. Long-term follow-up remains important because endovascular treatment requires surveillance for endoleaks, migration, sac enlargement, and limb complications. Japan also participates in multinational clinical research programs evaluating endovascular repair strategies.

• China Aortic Aneurysm Market Insights

China represents an estimated 5% share of the geographic structure. The country's large population creates significant potential for aneurysm diagnosis and treatment, while hospital modernization is increasing access to computed tomography angiography, vascular surgery, and endovascular intervention. Major urban medical centers have developed advanced vascular programs capable of performing EVAR, TEVAR, and complex endovascular procedures. The market is also influenced by increasing domestic medical-device development and government efforts to strengthen healthcare infrastructure. Demand opportunities include affordable endovascular grafts, advanced imaging systems, delivery technologies, physician training, and postoperative surveillance solutions. Clinical adoption differs between major metropolitan hospitals and lower-tier healthcare facilities, creating opportunities for broader specialist education. The development of domestic manufacturing capabilities can also influence pricing, supply security, and procurement. China's expanding cardiovascular-care infrastructure positions it as an important market for future aortic aneurysm treatment technologies.

• Middle East & Africa

The Middle East and Africa account for an estimated 2% share of the geographic structure. Demand is concentrated in countries with stronger hospital infrastructure, specialist cardiovascular centers, and greater healthcare investment. Gulf markets are developing advanced vascular programs, while several African markets continue to face limitations in specialist availability, diagnostic imaging, and access to sophisticated endovascular devices. The region offers opportunities for manufacturers that can provide physician training, regional distribution, service support, and cost-effective device portfolios. Endovascular procedures are increasingly attractive where advanced imaging and trained specialists are available because they can provide minimally invasive treatment for suitable anatomy. Demand is also supported by improvements in cardiovascular disease awareness and healthcare infrastructure. However, uneven reimbursement, import requirements, equipment costs, and limited specialist capacity remain important barriers. Partnerships with hospitals, distributors, and regional healthcare organizations can strengthen market penetration and improve access to aneurysm diagnosis and treatment.

Key Industry Players

The competitive landscape includes established medical-device companies with broad vascular portfolios, specialized endovascular manufacturers, and emerging companies developing focused aortic technologies. Medtronic, Gore Medical, Cook Medical, Endologix, Terumo Medical, MicroPort Scientific, and other suppliers compete through product breadth, clinical evidence, delivery-system improvements, regulatory approvals, physician training, and global distribution. Competitive positioning increasingly depends on the ability to treat complex anatomy while maintaining accurate deployment and durable sealing. Medtronic's clinical programs include randomized comparisons involving approximately 500 patients in the ADVANCE study, demonstrating the importance of evidence generation. Manufacturers are also strengthening manufacturing resilience and component supply chains through regulatory process updates and facility investments. Partnerships with hospitals, key opinion leaders, research organizations, and distributors remain important for adoption and geographic expansion.

List of Top Aortic Aneurysm Companies

• Medtronic
• Endologix
• Gore Medical
• MicroPort Scientific
• Cook Medical
• Terumo Medical
• MAQUET Holding
• Lombard Medical
• JOTEC
• Cardinal Health

List of Top Two Companies Market Share

• Medtronic: Estimated 18% market share, supported by Endurant, Valiant, Heli-FX, clinical evidence, and global physician adoption.
• Gore Medical: Estimated 15% market share, supported by Excluder, Conformable, Iliac Branch, and thoracic endovascular graft technologies.

Investment Analysis And Opportunities

Investment opportunities in the aortic aneurysm market center on minimally invasive devices, complex anatomy solutions, emergency treatment, advanced imaging, and long-term surveillance. Approximately 57% of identified innovation activity is concentrated around improvements in graft design, fixation, deployment, and sealing. Companies can prioritize investment in fenestrated and branched platforms, low-profile delivery systems, conformable grafts, endosuture technologies, and imaging-assisted procedural planning. Emerging markets provide additional opportunities through hospital modernization, specialist training, and improved access to vascular intervention. Manufacturing investment is also important because regulatory records from 2025 and 2026 show continued changes involving production lines, material suppliers, delivery components, and controlled manufacturing environments.

New Product Development

New product development is focused on improving deployment accuracy, anatomical compatibility, proximal fixation, sealing, and long-term durability. Approximately 2 major technology directions are particularly prominent: complex-anatomy endovascular platforms and improved emergency aneurysm treatment capabilities. Medtronic continues clinical evaluation of Endurant with Heli-FX EndoAnchor technology for wide-neck and short-neck aneurysms. Gore has also introduced regulatory modifications involving the delivery fiber and Conformable Excluder components during 2026, demonstrating ongoing refinement of device architecture. Development programs increasingly combine advanced polymers, nitinol structures, controlled deployment mechanisms, imaging compatibility, and enhanced sealing surfaces to address anatomically difficult aneurysms while supporting predictable procedural performance.

Aortic Aneurysm Five Recent Developments (2025–2026)

• October 2025 — Medtronic FDA labeling update expands emergency positioning for Endurant aneurysm treatment.

Medtronic received FDA approval removing the ruptured aneurysm treatment warning, incorporating clinical evidence and supporting emergency endovascular treatment capabilities.

• May 2026 — Gore Medical Excluder Conformable labeling update strengthens emergency ruptured aneurysm treatment positioning.

Gore Medical obtained FDA approval removing the ruptured aneurysm warning and adding supportive evidence within product labeling for emergency applications.

• May 2025 — Cook Medical  Zenith Iliac Branch approval expands endovascular treatment options for iliac aneurysm anatomy.

Cook Medical received FDA approval for Zenith Iliac Branch use, supporting internal iliac preservation and complex aortoiliac aneurysm treatment capabilities.

• April 2026 — MicroPort Scientific Hercules Thoracic Stent Graft labeling expansion broadens thoracic aortic treatment indications.

MicroPort Scientific received regulatory approval expanding the Hercules Thoracic Stent Graft indications to support a wider range of arch and descending thoracic aortic aneurysm anatomies.

• June 2026 — Endologix  Alto manufacturing update improves controlled sourcing for nitinol aneurysm graft production.

Endologix received FDA approval for an alternative nitinol-wire processing supplier, supporting manufacturing continuity and controlled production of the Alto abdominal stent graft.

• March 2026 — Terumo Aortic TREO system expansion adds longer graft configuration and delivery-system modifications.

Terumo Aortic received FDA approval adding a 140-millimeter contralateral length option and modifying the TREO delivery system to broaden anatomical treatment flexibility.

Aortic Aneurysm Market Report Coverage

The aortic aneurysm market report covers treatment types, application settings, regional demand, competitive positioning, investment opportunities, innovation activity, and recent industry developments. The analysis considers medicines, surgery, endovascular treatment, hospital services, clinics, diagnostic environments, and other supporting healthcare applications. Geographic coverage includes North America, Europe, Germany, the United Kingdom, Asia, Japan, China, and the Middle East and Africa. The competitive assessment covers 10 major companies, including Medtronic, Endologix, Gore Medical, MicroPort Scientific, Cook Medical, Terumo Medical, MAQUET Holding, Lombard Medical, JOTEC, and Cardinal Health. The report also evaluates regulatory developments, product modifications, clinical evidence, manufacturing changes, and technologies addressing complex aneurysm anatomy and emergency treatment.